Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
To the Editor, The gut microbiome is a dynamic population of microorganisms that modulate both local and systemic inflammatory responses [1.Derosa L. Hellmann M.D. Spaziano M. et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol. 2018; 29: 1437-1444Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar, 2.Gilbert J.A. Blaser M.J. Caporaso J.G. et al.Current understanding of the human microbiome.Nat Med. 2018; 24: 392Crossref PubMed Scopus (947) Google Scholar, 3.Vétizou M. Pitt J.M. Daillère R. et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science. 2015; 350: 1079Crossref PubMed Scopus (1929) Google Scholar]. Antibiotic (ATB)-induced alterations in the intestinal microbiota have been characterized with expansion in the relative abundance of specific species having been noted [4.Modi S.R. Collins J.J. Relman DA. Antibiotics and the gut microbiota.J Clin Invest. 2014; 124: 4212-4218Crossref PubMed Scopus (401) Google Scholar]. Interest in the effect of the microbiome and ATB-induced dysbacteriosis in oncologic treatment outcomes has heightened with the widespread use of immune checkpoint inhibitors (ICI). Previous reports suggest a potential relevance of microbiologic factors in the clinical activity of these drugs [1.Derosa L. Hellmann M.D. Spaziano M. et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol. 2018; 29: 1437-1444Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar, 3.Vétizou M. Pitt J.M. Daillère R. et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science. 2015; 350: 1079Crossref PubMed Scopus (1929) Google Scholar, 5.Routy B. Le Chatelier E. Derosa L. et al.Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors.Science. 2018; 359: 91Crossref PubMed Scopus (2587) Google Scholar]. Derosa et al. [1.Derosa L. Hellmann M.D. Spaziano M. et al.Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.Ann Oncol. 2018; 29: 1437-1444Abstract Full Text Full Text PDF PubMed Scopus (471) Google Scholar] recently demonstrated that ATB use within 30 days of beginning ICI had a negative impact on progression-free survival (PFS) and overall survival (OS) in patients with renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) treated with ICI. Whether ATB use is associated with PFS and OS in patients with other advanced cancers treated on ICI remains unclear. We recently published on the development of a prognostic scoring system for patients with advanced cancer enrolled in ICI phase I clinical trials [6.Sen S. Hess K. Hong D.S. et al.Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.Br J Cancer. 2018; 118: 763Crossref PubMed Scopus (18) Google Scholar]. Among those patients, we investigated the impact of ATB use on outcomes across tumor types in patients treated on phase I ICI trials at the MD Anderson Center from January 2013 to November 2015. Groups were compared for rate of primary progressive disease (PD), PFS, and OS. OS and PFS were estimated by the Kaplan–Meier method, and statistical significance was determined by the log-rank test. A total of 172 patients were analyzed (105 CTLA-4 based; 67 PD-1 based). Median age was 60.0 years, 49% were female. Of all patients analyzed, 38.9% were treated with ICI as a single-agent, and the remaining received combination therapy (26.7% with radiation, 18.6% with targeted therapy, and 15.7% with additional immunotherapy agents). Most common tumor types treated included RCC (14.5%), NSCLC (12.2%), melanoma (9.4%), sarcoma (9.4%), and gastrointestinal stromal tumors (5.8%). Twenty-six patients were not assessable for response; 1 patient experienced a CR and 13 patients achieved a PR (ORR = 9.5%), 57 had PD and 75 had SD as the best response. Overall, 57 patients used ATB—54 while on trial (all 54 used PO, 23 used IV as well), 19 patients in the 30-day before treatment and 14 patients 30–60 days preceding first treatment. The most commonly used ATB were quinolones (n = 39), β-lactams (n = 26), and tetracyclines (n = 7). There was no difference in the rate of primary PD with ATB use within 30 days of ICI (43% without ATB, 25% with ATB; P = 0.22) or with ATB use within 30–60 days of ICI (41% without ATB, 23% with ATB, P = 0.20). In addition, no difference was observed in PFS with ATB at all time points (Figure 1A–C). OS was significantly decreased in patients that received ATB in the 30-day before ICI initiation (Figure 1E). Our findings identify no significant difference in PFS or the rate of primary PD in patients t
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Previous reports suggest a potential relevance of microbiologic factors in the clinical activity of these drugs [1, 3, 5].”
BackgroundCurrent understanding of the human microbiome
Gilbert, J. A., Blaser, M. J., Caporaso, J. G., Jansson, J. K., Lynch, S. V., & Knight, R. (2018) · Nature Medicine · doi:10.1038/nm.4517 · Cited by 2,609 · cited 1×
“apparently considered only ‘certain’ cases in their calculations, excluding ‘probable/possible’ cases, which is incorrect as by such categories we classify only the basis of diagnosis [2].”
BackgroundDerosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908 · cited 2×
“[1] recently demonstrated that ATB use within 30 days of beginning ICI had a negative impact on progression-free survival (PFS) and overall survival (OS) in patients with renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC) treated with ICI.”
BackgroundAntibiotics and the Gut Microbiota
Modi, S. R., Collins, J. J., & Relman, D. A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72333 · Cited by 667
Cited by
Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.006 · Cited by 294
Tinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Wilson, B. E., Routy, B., Nagrial, A., & Chin, V. T. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02453-2 · Cited by 152
Huang, X.-Z., Gao, P., Song, Y.-X., Xu, Y., Sun, J.-X., Chen, X.-W., Zhao, J.-H., & Wang, Z.-N. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665973 · Cited by 132
“Of the eligible studies, eight studies were complete cohort studies(10,12,16,17,24,26,27,29) and 11 studies provided only an abstract.(13-15,18-23,25,28) The main characteristics of the included studies are listed in Table 1.”
BackgroundTakada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33557 · Cited by 100
Metadata
- Authors
- Sen, S., Carmagnani Pestana, R., Hess, K., Viola, G. M., & Subbiah, V.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 29
- Issue
- 12
- Pages
- 2396-2398
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2897664707
- Cited by
- 65
- References
- 5
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. https://app.cochat.ai/papers/10.1093/annonc/mdy453
- The paper
- Sen, S., Carmagnani Pestana, R., Hess, K., Viola, G. M., & Subbiah, V. (2018). Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Annals of Oncology. https://doi.org/10.1093/annonc/mdy453
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.